- In May 2024, the German Society for Pediatric Orthopedics launched a collaborative research program with Charité – Universitätsmedizin Berlin, aimed at advancing surgical techniques for complex multiple hereditary exostosis (MHE) cases in children. The initiative focuses on developing minimally invasive procedures and refining post-operative care protocols, enhancing mobility outcomes and reducing recurrence rates. This development highlights Germany’s leadership in pediatric rare disease care and its dedication to surgical innovation in MHE treatment
- In April 2024, Institut Curie in France initiated a multi-center clinical study to evaluate the long-term effectiveness of personalized physiotherapy programs in post-surgical MHE patients. The program integrates AI-driven motion tracking tools to monitor recovery and functional improvement. This research emphasizes France's commitment to integrating technology with patient-centric care approaches in managing hereditary skeletal disorders
- In March 2024, the UK National Health Service (NHS) included multiple hereditary exostosis under its Genomic Medicine Service rare disease diagnostic pathway. The new policy ensures access to free whole-genome sequencing for suspected MHE patients and their families, supporting early diagnosis and precision care. This strategic inclusion reflects the U.K.'s proactive stance in advancing rare disease genomics and improving healthcare equity
- In February 2024, Rizzoli Orthopaedic Institute in Italy announced the development of a specialized imaging protocol for early-stage detection of MHE in children. Utilizing high-resolution 3D imaging techniques, the protocol aims to reduce diagnostic ambiguity and improve pre-surgical planning. Italy’s investment in imaging technology reflects its growing role in orthopedic research and personalized care
- In January 2024, Fundación Española de Enfermedades Raras (FEDER) in Spain partnered with local health authorities to launch a national awareness campaign on hereditary bone diseases, including MHE. The campaign aims to improve early recognition, promote genetic testing, and reduce diagnostic delays. This initiative underscores Spain’s growing commitment to community-based education and rare disease advocacy
